Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.61 |
| ▸ | PPARG | P37231 | 8/20 | 0.59 |
| ▸ | PPARD | Q03181 | 6/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20125593 | 1.00 | PPARA (0.61) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL29358494 | 1.00 | PPARA (0.61) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL14379043 | 1.00 | PPARA (0.61) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL896413 | 0.93 | PPARG (0.52) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6239522 | 0.91 | PPARA (0.59) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL7465714 | 0.91 | PPARG (0.50) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL7462895 | 0.90 | PPARA (0.52) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL13524845 | 0.89 | PTPN1 (0.55) | PPARAPPARGPPARDPTPN1 | |
| SCHEMBL6376424 | 0.89 | POLB (0.54) | PPARAPPARGPPARDPTPN1 | |
| SCHEMBL13847876 | 0.88 | PTPN1 (0.54) | PPARAPPARGPPARDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 913 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | claimed |
| EP-1942898-B2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-14 | — | — | EP | claimed |
| EP-1931350-B1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-20 | — | — | EP | claimed |
| US-8338480-B2 | Combination treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | claimed |
| EP-1942898-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | claimed |
| US-20110212982-A1 | Administration of Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | claimed |
| US-20110192748-A1 | Administration of Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | US | claimed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | claimed |
| US-20100292277-A1 | COMBINATION TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-11-18 | — | — | US | claimed |
| EP-1253145-A1 | ALKALI METAL SALT OF THIAZOLIDINE-2,4-DIONE DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | claimed |
| EP-1243266-A1 | SOLID PREPARATIONS FOR ORAL USE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | claimed |
| EP-0846693-B1 | N-BENZYLDIOXOTHIAZOLIDYLBENZAMIDE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | KYORIN SEIYAKU KK (JP) | 2002-01-23 | — | — | EP | claimed |
| CN-1069901-C | N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same | KYORIN SEIYAKU KK (JP) | 2001-08-22 | — | — | CN | claimed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | claimed |
| US-6147101-A | TREATING HYPERGLYCEMIA | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-11-14 | — | — | US | claimed |
| US-6030990-A | ANTIDIABETIC AND -LIPEMIC AGENTS; PARTICULARLY FOR NON-INSULIN DEPENDENT DIABETES MELLITUS, A BLOOD SUGAR-LOWERING DRUG THAT IMPROVES THE INSULIN RESISTANCE AND HAS HIGH SAFETY AND EFFICIENCY | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-02-29 | — | — | US | claimed |
| US-6001862-A | ADMINISTERING TO A PATIENT SUFFERING FROM NON-INSULIN DEPENDENT DIABETES MELLITUS A N-BENZYLDIOXOTHIAZOLIDYLBENZAMIDE COMPOUND | KYORIN PHARAMEUTICALS CO., LTD. (JP) | 1999-12-14 | — | — | US | claimed |
| CN-1186489-A | N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same | KYORIN SEIYAKU KK (JP) | 1998-07-01 | — | — | CN | claimed |
| EP-0846693-A1 | N-BENZYLDIOXOTHIAZOLIDYLBENZAMIDE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1998-06-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110192748-A1 | Administration of Dipeptidyl Peptidase Inhibitors | DPP4, DPP7, DPP3 | PPARA 1631/4885PPARG 2134/4885PPARD 1267/4885 |
| US-20100292277-A1 | COMBINATION TREATMENT OF METABOLIC DISORDERS | NR1H3, GPR119, NR1H2 | PPARA 13/4885PPARG 12/4885PPARD 7/4885 |
| US-20110212982-A1 | Administration of Dipeptidyl Peptidase Inhibitors | DPP4, DPP7, DPP3 | PPARA 1793/4885PPARG 2282/4885PPARD 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.